WORLDLINE 10.274 € (+1,02 %) 
BE SEMICONDUCTOR 163.050 € (+11,41 %) TOTALENERGIES 83.000 € (-1,00 %) 
SHELL PLC 47.130 € (-1,63 %) AIR LIQUIDE 174.440 € (-0,52 %) PERNOD RICARD 66.420 € (-1,92 %) DRONE VOLT 0.210 € (-4,02 %) SECHE ENVIRONNEM. 74.500 € (+2,48 %) ASML HOLDING 1 470.000 € (+2,80 %) STELLANTIS NV 3.713 € (+0,54 %) HEINEKEN 76.780 € (-0,60 %) ASM INTERNATIONAL 743.200 € (+5,00 %) THALES 234.200 € (+0,56 %) AIRBUS 192.740 € (-0,34 %) KAUFMAN ET BROAD 19.440 € (+0,21 %) LEGRAND 129.050 € (+2,46 %) SCHNEIDER ELECTRIC 242.700 € (+2,97 %) STMICROELECTRONICS 43.360 € (+7,06 %) ENGIE 23.370 € (+0,26 %) ALFEN 10.160 € (+2,11 %) AXA 42.460 € (+0,31 %) ADYEN 944.000 € (+1,94 %) AKZO NOBEL 58.840 € (+0,07 %) VIRBAC 348.500 € (-0,14 %) LAKEFRONT BIOTHER. 28.220 € (0,00 %) EXOSENS 56.800 € (-4,78 %) HERMES INTL 1 268.500 € (-0,78 %) VIVENDI SE 1.561 € (+3,17 %) TELEPERFORMANCE 80.160 € (-0,77 %) AYVENS 8.715 € (-0,11 %) EASE2PAY NV 0.594 € (+13,36 %) GTT 188.100 € (+3,87 %) SANOFI 75.150 € (+0,76 %) FUGRO 7.905 € (+3,27 %) CORBION 27.200 € (+8,19 %) RELX 35.160 € (-1,95 %) IMCD 101.000 € (+0,85 %) HOPIUM 0.003 € (+3,23 %) ORANGE 14.260 € (0,00 %) NEXITY 4.254 € (-1,30 %) OCI 4.122 € (+0,24 %) ELIS 22.180 € (-0,45 %) 74SOFTWARE 37.600 € (0,00 %) GECINA 63.650 € (-0,47 %) ING GROEP N.V. 29.250 € (+0,74 %) ABN AMRO BANK N.V. 40.180 € (+1,13 %) ASR NEDERLAND 75.520 € (+0,91 %) POXEL 0.163 € (-2,40 %) CRCAM LANGUED CCI 63.000 € (+0,64 %) ALSTOM 16.185 € (-0,61 %) MAISONS DU MONDE 0.182 € (-2,26 %) OVH 13.430 € (+6,76 %) AVANTIUM 3.900 € (-13,62 %) VEOLIA ENVIRON. 32.620 € (+0,55 %) EURONEXT 177.100 € (+0,11 %) EIFFAGE 100.400 € (+0,70 %) PUBLICIS GROUPE SA 99.660 € (+0,40 %) MICHELIN 31.790 € (-0,16 %) SAINT GOBAIN 67.840 € (+0,30 %) DANONE 61.620 € (-0,61 %) |
30/09/2026 17:45
EQS-Adhoc: Viromed Medical AG: Study on cold plasma application in the lung accepted for publication by an internationally leading medical journalEQS-Ad-hoc: Viromed Medical AG / Key word(s): Other Viromed Medical AG: Study on cold plasma application in the lung accepted for publication by an internationally leading medical journal Rellingen, 30 September 2026 – Viromed Medical AG (“Viromed”; ISIN: DE000A40ZVN7) announces that a scientific paper on the results of the study on the application of cold atmospheric plasma in the lung has cleared this high hurdle and has been accepted by an internationally leading medical journal. Viromed was informed of this by the scientific leadership of the study. The study was prepared and submitted under the scientific leadership of Prof. Dr. Hortense Slevogt, Hannover Medical School and Helmholtz Centre for Infection Research. Uwe Perbandt, CEO of Viromed Medical AG, is a co-author of the paper. The study addresses the application of cold atmospheric plasma in severe infectious lung diseases, in particular in connection with ventilator-associated pneumonia. A significant, pathogen-independent reduction of pathogenic germs was demonstrated, together with a clearly defined therapeutic safety window. Histological analyses and further examinations showed no safety-relevant tissue damage within this application window. The scientific details of the study will be communicated by the participating scientists after publication of the paper. Notifying person: Uwe Perbandt, CEO of Viromed Medical AG Contact Viromed: E-mail: kontakt@viromed-medical.de End of Inside Information 30-Sep-2026 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
2408210 30-Sep-2026 CET/CEST Source : Webdisclosure.com |
||||||||||||||||||||||||||||||
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière